THERAVANCE BIOPHARMA INC
NASDAQ: TBPH (Theravance Biopharma, Inc.)
Kemas kini terakhir: 1 jam lalu17.01
-0.01 (-0.06%)
| Penutupan Terdahulu | 17.02 |
| Jumlah Dagangan | 420,492 |
| Harga / Pendapatan (P/E Ke hadapan) | 9.73 |
| Harga / Jualan (P/S) | 8.47 |
| Harga / Buku (P/B) | 3.05 |
| Julat 52 Minggu |
| Margin Keuntungan | -89.38% |
| Margin Operasi (TTM) | -93.80% |
| EPS Cair (TTM) | -1.18 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 6.10% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 29.01% |
| Nisbah Semasa (MRQ) | 4.77 |
| Aliran Tunai Operasi (OCF TTM) | 32.53 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 4.64 M |
| Pulangan Atas Aset (ROA TTM) | -7.98% |
| Pulangan Atas Ekuiti (ROE TTM) | -31.46% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Theravance Biopharma, Inc. | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | 2.0 |
| Purata | 0.50 |
|
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 4.48% |
| % Dimiliki oleh Institusi | 91.75% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Madison Avenue Partners, Lp | 30 Jun 2026 | 9,212,252 |
| Weiss Asset Management Lp | 30 Jun 2026 | 7,457,060 |
| Newtyn Management, Llc | 30 Jun 2026 | 3,434,191 |
| Irenic Capital Management Lp | 30 Jun 2026 | 2,760,948 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |